Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine

L. E. Shapiro, R. Sievert, L. Ong, E. L. Ocampo, R. A. Chance, M. Lee, M. Nanna, Kevin J. Ferrick, Martin I. Surks

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Biondi, Fazio, and colleagues recently reported that long term T4 treatment to suppress serum TSH markedly affects cardiac function. T4- treated patients had more symptoms [12.2 ± 3.9 (±SD) vs. 4.2 ± 2.3 by quantitative questionnaire], higher mean heart rate, increased incidence of atrial extrasystoles, increased interventricular septal thickness and left ventricular mass index [LVMi), and significant diastolic dysfunction. The severity of cardiac abnormalities was highly correlated with scores of a rating scale used for assessing symptoms of thyrotoxicosis. We have duplicated their studies in 17 athyreotic patients (mean age, 45 ± 10 yr; range, 27-63 yr) without heart disease or hypertension whose dose of T4 was titrated to suppress serum TSH to less than 0.01 μU/mL. The mean duration of T4 treatment was 9.2 ± 5.4 yr. Controls were healthy volunteers matched for sex and age (±3 yr). The mean T4 dose was 2.8 ± 0.9 μg/kg (0.192 ± 0.058 mg/day). By questionnaire, patients had minimalsymptoms, although their symptom score was significantly greater than the control value (4 ± 3 vs. 2 ± 1; P < 0.05; maximum score, 36). No differences in mean heart rate or in atrial or ventricular extra-systoles were noted. In patients, indexes of systolic and diastolic function and interventricular septal thickness were similar to control values. The mean LVMi was normal in both groups. However, the mean LVMi in patients (117 ± 35 g/m2) was higher than that in controls (92 ± 31; P < 0.05). In conclusion, patients were minimally affected by TSH- suppressive doses of T4. They had few symptoms and no increase in extrasystoles or basal heart rate. Based on current knowledge, the increase in LVMi observed in patients without associated significant systolic or diastolic abnormalities does not have clinical or prognostic importance. Therefore, in the absence of symptoms of thyrotoxicosis, patients treated with TSH-suppressive doses of L-T4 may be followed clinically without specific cardiac laboratory studies.

Original languageEnglish (US)
Pages (from-to)2592-2595
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume82
Issue number8
DOIs
StatePublished - 1997

Fingerprint

Thyrotropin
Thyroxine
Thyrotoxicosis
Heart Rate
Atrial Premature Complexes
Premature Cardiac Complexes
Serum
Heart Diseases
Healthy Volunteers
Hypertension
Incidence
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. / Shapiro, L. E.; Sievert, R.; Ong, L.; Ocampo, E. L.; Chance, R. A.; Lee, M.; Nanna, M.; Ferrick, Kevin J.; Surks, Martin I.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 8, 1997, p. 2592-2595.

Research output: Contribution to journalArticle

@article{f221eafe009d4d47aa7b2db03d066fb3,
title = "Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine",
abstract = "Biondi, Fazio, and colleagues recently reported that long term T4 treatment to suppress serum TSH markedly affects cardiac function. T4- treated patients had more symptoms [12.2 ± 3.9 (±SD) vs. 4.2 ± 2.3 by quantitative questionnaire], higher mean heart rate, increased incidence of atrial extrasystoles, increased interventricular septal thickness and left ventricular mass index [LVMi), and significant diastolic dysfunction. The severity of cardiac abnormalities was highly correlated with scores of a rating scale used for assessing symptoms of thyrotoxicosis. We have duplicated their studies in 17 athyreotic patients (mean age, 45 ± 10 yr; range, 27-63 yr) without heart disease or hypertension whose dose of T4 was titrated to suppress serum TSH to less than 0.01 μU/mL. The mean duration of T4 treatment was 9.2 ± 5.4 yr. Controls were healthy volunteers matched for sex and age (±3 yr). The mean T4 dose was 2.8 ± 0.9 μg/kg (0.192 ± 0.058 mg/day). By questionnaire, patients had minimalsymptoms, although their symptom score was significantly greater than the control value (4 ± 3 vs. 2 ± 1; P < 0.05; maximum score, 36). No differences in mean heart rate or in atrial or ventricular extra-systoles were noted. In patients, indexes of systolic and diastolic function and interventricular septal thickness were similar to control values. The mean LVMi was normal in both groups. However, the mean LVMi in patients (117 ± 35 g/m2) was higher than that in controls (92 ± 31; P < 0.05). In conclusion, patients were minimally affected by TSH- suppressive doses of T4. They had few symptoms and no increase in extrasystoles or basal heart rate. Based on current knowledge, the increase in LVMi observed in patients without associated significant systolic or diastolic abnormalities does not have clinical or prognostic importance. Therefore, in the absence of symptoms of thyrotoxicosis, patients treated with TSH-suppressive doses of L-T4 may be followed clinically without specific cardiac laboratory studies.",
author = "Shapiro, {L. E.} and R. Sievert and L. Ong and Ocampo, {E. L.} and Chance, {R. A.} and M. Lee and M. Nanna and Ferrick, {Kevin J.} and Surks, {Martin I.}",
year = "1997",
doi = "10.1210/jc.82.8.2592",
language = "English (US)",
volume = "82",
pages = "2592--2595",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine

AU - Shapiro, L. E.

AU - Sievert, R.

AU - Ong, L.

AU - Ocampo, E. L.

AU - Chance, R. A.

AU - Lee, M.

AU - Nanna, M.

AU - Ferrick, Kevin J.

AU - Surks, Martin I.

PY - 1997

Y1 - 1997

N2 - Biondi, Fazio, and colleagues recently reported that long term T4 treatment to suppress serum TSH markedly affects cardiac function. T4- treated patients had more symptoms [12.2 ± 3.9 (±SD) vs. 4.2 ± 2.3 by quantitative questionnaire], higher mean heart rate, increased incidence of atrial extrasystoles, increased interventricular septal thickness and left ventricular mass index [LVMi), and significant diastolic dysfunction. The severity of cardiac abnormalities was highly correlated with scores of a rating scale used for assessing symptoms of thyrotoxicosis. We have duplicated their studies in 17 athyreotic patients (mean age, 45 ± 10 yr; range, 27-63 yr) without heart disease or hypertension whose dose of T4 was titrated to suppress serum TSH to less than 0.01 μU/mL. The mean duration of T4 treatment was 9.2 ± 5.4 yr. Controls were healthy volunteers matched for sex and age (±3 yr). The mean T4 dose was 2.8 ± 0.9 μg/kg (0.192 ± 0.058 mg/day). By questionnaire, patients had minimalsymptoms, although their symptom score was significantly greater than the control value (4 ± 3 vs. 2 ± 1; P < 0.05; maximum score, 36). No differences in mean heart rate or in atrial or ventricular extra-systoles were noted. In patients, indexes of systolic and diastolic function and interventricular septal thickness were similar to control values. The mean LVMi was normal in both groups. However, the mean LVMi in patients (117 ± 35 g/m2) was higher than that in controls (92 ± 31; P < 0.05). In conclusion, patients were minimally affected by TSH- suppressive doses of T4. They had few symptoms and no increase in extrasystoles or basal heart rate. Based on current knowledge, the increase in LVMi observed in patients without associated significant systolic or diastolic abnormalities does not have clinical or prognostic importance. Therefore, in the absence of symptoms of thyrotoxicosis, patients treated with TSH-suppressive doses of L-T4 may be followed clinically without specific cardiac laboratory studies.

AB - Biondi, Fazio, and colleagues recently reported that long term T4 treatment to suppress serum TSH markedly affects cardiac function. T4- treated patients had more symptoms [12.2 ± 3.9 (±SD) vs. 4.2 ± 2.3 by quantitative questionnaire], higher mean heart rate, increased incidence of atrial extrasystoles, increased interventricular septal thickness and left ventricular mass index [LVMi), and significant diastolic dysfunction. The severity of cardiac abnormalities was highly correlated with scores of a rating scale used for assessing symptoms of thyrotoxicosis. We have duplicated their studies in 17 athyreotic patients (mean age, 45 ± 10 yr; range, 27-63 yr) without heart disease or hypertension whose dose of T4 was titrated to suppress serum TSH to less than 0.01 μU/mL. The mean duration of T4 treatment was 9.2 ± 5.4 yr. Controls were healthy volunteers matched for sex and age (±3 yr). The mean T4 dose was 2.8 ± 0.9 μg/kg (0.192 ± 0.058 mg/day). By questionnaire, patients had minimalsymptoms, although their symptom score was significantly greater than the control value (4 ± 3 vs. 2 ± 1; P < 0.05; maximum score, 36). No differences in mean heart rate or in atrial or ventricular extra-systoles were noted. In patients, indexes of systolic and diastolic function and interventricular septal thickness were similar to control values. The mean LVMi was normal in both groups. However, the mean LVMi in patients (117 ± 35 g/m2) was higher than that in controls (92 ± 31; P < 0.05). In conclusion, patients were minimally affected by TSH- suppressive doses of T4. They had few symptoms and no increase in extrasystoles or basal heart rate. Based on current knowledge, the increase in LVMi observed in patients without associated significant systolic or diastolic abnormalities does not have clinical or prognostic importance. Therefore, in the absence of symptoms of thyrotoxicosis, patients treated with TSH-suppressive doses of L-T4 may be followed clinically without specific cardiac laboratory studies.

UR - http://www.scopus.com/inward/record.url?scp=0030852904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030852904&partnerID=8YFLogxK

U2 - 10.1210/jc.82.8.2592

DO - 10.1210/jc.82.8.2592

M3 - Article

C2 - 9253339

AN - SCOPUS:0030852904

VL - 82

SP - 2592

EP - 2595

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -